|
1
|
Brierley JD, Gospodarowicz MK and
Wittekind C: Digestive system tumours. TNM Classification of
Malignant Tumours. 8th edition. Wiley-Blackwell; Oxford: pp. 83–90.
2017
|
|
2
|
Rizvi S and Gores GJ: Pathogenesis,
diagnosis, and management of cholangiocarcinoma. Gastroenterology.
145:1215–1229. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hoyos S, Navas MC, Restrepo JC and Botero
RC: Current controversies in cholangiocarcinoma. Biochim Biophys
Acta Mol Basis Dis. 1864:1461–1467. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Khan SA, Tavolari S and Brandi G:
Cholangiocarcinoma: Epidemiology and risk factors. Liver Int. 39
(Suppl 1):19–31. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Matsukuma S, Tokumitsu Y, Shindo Y, Matsui
H and Nagano H: Essential updates to the surgical treatment of
biliary tract cancer. Ann Gastroenterol Surg. 3:378–389. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chang K, Pai LH, Pass H, Pogrebniak HW,
Tsao MS, Pastan I and Willingham MC: Monoclonal antibody K1 reacts
with epithelial mesothelioma but not with lung adenocarcinoma. Am J
Surg Pathol. 16:259–268. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chang K and Pastan I: Molecular cloning of
mesothelin, a differentiation antigen present on mesothelium,
mesotheliomas, and ovarian cancers. Proc Natl Acad Sci USA.
93:136–140. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Argani P, Iacobuzio-Donahue C, Ryu B,
Rosty C, Goggins M, Wilentz RE, Murugesan SR, Leach SD, Jaffee E,
Yeo CJ, et al: Mesothelin is overexpressed in the vast majority of
ductal adenocarcinomas of the pancreas: Identification of a new
pancreatic cancer marker by serial analysis of gene expression
(SAGE). Clin Cancer Res. 7:3862–3868. 2001.PubMed/NCBI
|
|
9
|
Ordóñez NG: Application of mesothelin
immunostaining in tumor diagnosis. Am J Surg Pathol. 27:1418–1428.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ho M, Hassan R, Zhang J, Wang QC, Onda M,
Bera T and Pastan I: Humoral immune response to mesothelin in
mesothelioma and ovarian cancer patients. Clin Cancer Res.
11:3814–3820. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Einama T, Kamachi H, Nishihara H, Homma S,
Kanno H, Takahashi K, Sasaki A, Tahara M, Okada K, Muraoka S, et
al: Co-expression of mesothelin and CA125 correlates with
unfavorable patient outcome in pancreatic ductal adenocarcinoma.
Pancreas. 40:1276–1282. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hassan R, Bera T and Pastan I: Mesothelin:
A new target for immunotherapy. Clin Cancer Res. 10:3937–3942.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rump A, Morikawa Y, Tanaka M, Minami S,
Umesaki N, Takeuchi M and Miyajima A: Binding of ovarian cancer
antigen CA125/MUC16 to mesothelin mediates cell adhesion. J Biol
Chem. 279:9190–9198. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kaneko O, Gong L, Zhang J, Hansen JK,
Hassan R, Lee B and Ho M: A binding domain on mesothelin for
CA125/MUC16. J Biol Chem. 284:3739–3749. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gubbels JAA, Belisle J, Onda M, Rancourt
C, Migneault M, Ho M, Bera TK, Connor J, Sathyanarayana BK, Lee B,
et al: Mesothelin-MUC16 binding is a high affinity, N-glycan
dependent interaction that facilitates peritoneal metastasis of
ovarian tumors. Mol Cancer. 5:502006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kawamata F, Kamachi H, Einama T, Homma S,
Tahara M, Miyazaki M, Tanaka S, Kamiyama T, Nishihara H, Taketomi
A, et al: Intracellular localization of mesothelin predicts patient
prognosis of extrahepatic bile duct cancer. Int J Oncol.
41:2109–2118. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nomura R, Fujii H, Abe M, Sugo H, Ishizaki
Y, Kawasaki S and Hino O: Mesothelin expression is a prognostic
factor in cholangiocellular carcinoma. Int Surg. 98:164–169. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
He X, Wang L, Riedel H, Wang K, Yang Y,
Dinu CZ and Rojanasakul Y: Mesothelin promotes
epithelial-to-mesenchymal transition and tumorigenicity of human
lung cancer and mesothelioma cells. Mol Cancer. 16:632017.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Einama T, Homma S, Kamachi H, Kawamata F,
Takahashi K, Takahashi N, Taniguchi M, Kamiyama T, Furukawa H,
Matsuno Y, et al: Luminal membrane expression of mesothelin is a
prominent poor prognostic factor for gastric cancer. Br J Cancer.
107:137–142. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kawamata F, Homma S, Kamachi H, Einama T,
Kato Y, Tsuda M, Tanaka S, Maeda M, Kajino K, Hino O, et al:
C-ERC/mesothelin provokes lymphatic invasion of colorectal
adenocarcinoma. J Gastroenterol. 49:81–92. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang J, Bo X, Nan L, Wang CC, Gao Z, Suo
T, Ni X, Liu H, Lu P, Wang Y, et al: Landscape of distant
metastasis mode and current chemotherapy efficacy of the advanced
biliary tract cancer in the United States, 2010–2016. Cancer Med.
9:1335–1348. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hasebe T, Konishi M, Iwasaki M, Endoh Y,
Nakagohri T, Takahashi S, Kinoshita T and Ochiai A: Histological
characteristics of tumor cells and stromal cells in vessels and
lymph nodes are important prognostic parameters of extrahepatic
bile duct carcinoma: A prospective study. Hum Pathol. 36:655–664.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Noji T, Miyamoto M, Kubota KC, Shinohara
T, Ambo Y, Matsuno Y, Kashimura N and Hirano S: Evaluation of extra
capsular lymph node involvement in patients with extra-hepatic bile
duct cancer. World J Surg Oncol. 10:1062012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Shimizu A, Hirono S, Tani M, Kawai M,
Okada K, Miyazawa M, Kitahata Y, Nakamura Y, Noda T, Yokoyama S, et
al: Coexpression of MUC16 and mesothelin is related to the invasion
process in pancreatic ductal adenocarcinoma. Cancer Sci.
103:739–746. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chen SH, Hung WC, Wang P, Paul C and
Konstantopoulos K: Mesothelin binding to CA125/MUC16 promotes
pancreatic cancer cell motility and invasion via MMP-7 activation.
Sci Rep. 3:18702013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ishida K, Osakabe M, Eizuka M, Tai S,
Sugimoto R, Fujita Y, Katagiri H, Takahara T, Uesugi N, Nitta H, et
al: The expression of gastrointestinal differentiation markers in
extrahepatic cholangiocarcinoma: Clinicopathological significance
based on tumor location. Hum Pathol. 92:91–100. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Nakamura H, Arai Y, Totoki Y, Shirota T,
Elzawahry A, Kato M, Hama N, Hosoda F, Urushidate T, Ohashi S, et
al: Genomic spectra of biliary tract cancer. Nat Genet.
47:1003–1010. 2015. View
Article : Google Scholar : PubMed/NCBI
|
